Kornimate/medical-research-clean huggingface dataset:
observational study on the use of ivermectin as an outpatient treatment option for covid-19

Conditions: Covid19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; COVID-19 Acute Bronchitis

Summary: ivermectin is currently being utilized by a number of physicians in the local area. my objective will be to enroll these patients at the time of their evaluation for covid-19 infection and to follow their progress through their recovery.

patients at local physician clinics as well as my own clinic will be enrolled at the time they are evaluated for having covid-19. patients enrollment will be voluntary and based upon their request for treatment with ivermectin. these patients will be questioned on symptoms and the timing of those symptoms in detail. they will then be followed throughout their treatment course to evaluate their recovery experience. detailed accounts of their symptoms and their resolution will be followed. the study patients will stop being followed when they are either admitted to the hospital or are deemed to be symptom free. any other medications prescribed to the patients will also be tracked. medical histories will be taken and documented to make comparisons at the end of the study. those patients not requesting ivermectin will also be followed for comparisons at a later date.

Eligibility criteria:
inclusion criteria: * between the ages of 12-110 years old * has a recently completed covid test * symptomatic and seeking treatment * willingness to participate and have follow-up * able and willing to take medications and treatment suggestions from the physician exclusion criteria: lack of symptoms, uncertain of covid-19 status, outside of age limits for treatment * no recent covid test results * asymptomatic, even if covid positive * outside of acceptable age range * meets criteria for hospital admission * unwilling to participate in trial study or have follow-up
clinical results of bisphosphonate and denosumab therapy following teriparatide therapy for japanese

Conditions: Osteoporosis

Summary: in this study, the investigators would like to analyze the bone mineral density (bmd) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in japanese patients under clinical practice. the participants are treated in the investigators hospital, who are under severe osteoporotic condition.

registry criteria: patients treated in the investigators hospital using teriparatide. enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low bmd (\< young adult mean 65%). interventions: blood analyses and dual-energy x-ray absorptiometry (dxa) every 4 months informed consent: written informed consent will be obtained. sample size: five-hundreds participants

Eligibility criteria:
inclusion criteria: * severe osteoporotic patients exclusion criteria: * cancer, hypercalcemia, etc (i.e. patients who could not use bisphosphonate, denosmab, teriparatide)

Keywords: osteoporosis bmd teriparatide bisphosphonate denosmab
exploring the association of imaging and tumor microenvironment in urologic cancer using radiogenomic approach（radiogenomics-urinary）

Conditions: Urologic Cancer

Summary: this is the prospective, observational cohort study (radiogenomics-urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic cancer patients.


Eligibility criteria:
inclusion criteria: 1. patients treated for urologic cancer in wuhan union hospital from august 2024 to august 2027; 2. aged \> 18 years old; 3. at least one ct scan or mri scan before treatment; 4. tissue biopsy pathological examination confirmed the diagnosis of the above tumors. exclusion criteria： 1. poor image quality; 2. incomplete clinical data or loss of follow-up; 3. presence of another primary malignancy other than urologic cancer; 4. unclear pathological diagnosis。
safety and efficacy of itacitinib in participants with bronchiolitis obliterans syndrome following lung transplantation

Conditions: Bronchiolitis Obliterans Syndrome

Summary: the purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (bos).


Eligibility criteria:
inclusion criteria: * double lung transplantation ≥ 1 year before informed consent. confirmed bos progression to grade 1, 2, or 3 diagnosed within 1 year of screening \*confirmed bos progression to grade 1, 2, or 3 diagnosed within 2 years of screening and: * a ≥ 200 ml decrease in fev1 in the previous 12 months or \*a ≥ 50 ml decrease in fev1 in the last 2 measurements. • willingness to avoid pregnancy or fathering children. exclusion criteria: * history of a single lung transplant * fev1 decline attributable to cause(s) other than bos. * participants who have had any significant change (eg, addition of new agents) in an immunosuppressive regimen in the 4 weeks before screening. * untreated and/or symptomatic gastroesophageal reflux disease. * significant infectious comorbidities including invasive fungal disease, b. cepacia, non tb mycobacteria, or tb. * receipt of jak inhibitor therapy after lung transplant for any indication. treatment with a jak inhibitor before lung transplant is permitted. * laboratory values at screening outside the protocol-defined ranges. * active hbv or hcv infection that requires treatment, or at risk for hbv reactivation (ie, positive hbsag). * known hiv infection. * history of active malignancy within 3 years of screening. * women who are pregnant or breastfeeding. * treatment with an investigational agent, procedure, or device within 30 days of enrollment, or within 5 half-lives of the investigational product, whichever is longer.

Keywords: bronchiolitis obliterans syndrome lung transplant jak1 inhibitor
daily habits & consumer preferences study

Conditions: Obesity

Summary: the study will use a between-subjects design in a sample of individuals with bmi greater than or equal to 28 from the los angeles community (n=330). participants will be randomly assigned to a weight stigma vs. control manipulation. changes to the following health behaviors will be subsequently measured in their everyday lives: 3-day diet as captured by ecological momentary assessment (ema) food diaries, objectively measured eating of obesogenic foods, objectively measured physical activity captured by 24-hour actigraphy, and sleep, captured objectively by overnight actigraphy and subjectively self-reported sleep measures. the investigators hypothesize that weight stigma causes decrements in health behaviors (e.g., sleep, eating, and physical activity) in everyday life.


Eligibility criteria:
inclusion criteria: 1. age 18+ 2. english-speaking 3. bmi greater than or equal to 28 exclusion criteria: 1. major mental disorder including eating disorder, mood disorder, schizophrenia, ptsd 2. recent (\<1 year) diagnosis of major physical conditions that limit physical movement 3. recent (\<1 year) diagnosis of sleep disorder 4. allergy to any of the foods in the food buffet

Keywords: weight prejudice sleep eating exercise ecological momentary assessment actigraphy diet records
gene expression profiles to categorize wilms tumors

Conditions: Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Stage I Wilms Tumor; Stage II Wilms Tumor; Stage III Wilms Tumor; Stage IV Wilms Tumor; Stage V Wilms Tumor

Summary: this laboratory study is using gene expression profiling to identify different categories of wilms tumors. studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.

objectives: i. identify new molecular categories of wilms tumor (wt) based on the gene expression profiles of samples from patients with this disease. ii. develop a classifying system (classifier) that will predict a defined number of clinically relevant categories based on expression of an established set of genes. iii. confirm and test the classifier with further analysis of the genes by several different methodologies, using additional patient samples that are outside of the case/cohort but which possess the clinically or scientifically relevant parameter. iv. validate the use of the classifier to predict defined groups within a second set of samples (for which investigators are blinded to the clinical and biological data) by subsequent comparison with true incidence of pertinent markers. outline: three hundred tumor specimens are analyzed for genetic expression profiles using affymetrix assays. specific genes are identified as classifiers and analyzed using tissue arrays. an additional 300 specimens are examined for gene expression and categorized according to the classifiers.

Eligibility criteria:
inclusion criteria: * specimens from patients previously enrolled as "on study" or "followed biology only" on protocol nwtsg-5 (cog-q9401) * study follow-up data for disease status available * national wilms tumor study group/children's oncology group pathology review showing "favorable" histology * sufficient biology samples available without using biology bank reserves
anxiety, mood, and health behaviors in young adults

Conditions: Anxiety Sensitivity

Summary: this is a randomized control trial to test the effect of an anxiety sensitivity intervention on health behaviors among 18-35 year-olds.

this is a 2-arm randomized control trial to test the effect of an anxiety sensitivity intervention on health behaviors among 18-35 year-olds. participants will be 18-35 year-olds with high anxiety sensitivity randomized to 1)exercise exposure intervention or 2)assessment only control condition. participants in both groups will be followed for 8 weeks.

Eligibility criteria:
inclusion criteria: * ages 18-35 * elevated anxiety sensitivity (asi-3 score \>=23) * able to safely participate in moderate-intensity physical activity as assessed by the physical activity readiness questionnaire (par-q), which will be administered during screening exclusion criteria: * current aerobic exercise routine - measured using the l-cat with an established cut point of \>2 (assessed at screening) * receiving ongoing psychotherapy or counseling (self-report at screening) * recent change in psychotropic medication for anxiety (self-report at screening) * psychiatric hospitalization in past 6 months (self-report at screening) * current pregnancy (self-report at screening)

Keywords: anxiety young adults health behaviors
evaluation of safety of cabazitaxel (jevtana) in patients with metastatic hormone refractory prostate cancer

Conditions: Prostate Cancer Metastatic

Summary: primary objective: to evaluate the safety of cabazitaxel (jevtana) in patients with metastatic hormone refractory prostate cancer secondary objectives: 1. to describe the use of cabazitaxel (jevtana) in combination with oral prednisolone for the treatment of patients with metastatic hormone refractory prostate cancer 2. to describe patient profile in terms of demography, disease characteristics and prior treatment history 3. to describe efficacy outcomes: radiological response (if available) using recist criteria v 1.1 and prostate specific antigen (psa) response

the study consists of: * a screening phase (maximum length of 7-day). * a treatment phase with 21-day study treatment cycles. patients continue to receive treatment until disease progression , death, unacceptable toxicity, investigator's decision or withdrawal of consent. * a 30-day follow-up visit after the last dose of study medication.

Eligibility criteria:
inclusion criteria : * metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-containing regimen * disease progression during or after docetaxel-containing regimen for mhrpc * surgical or medical castration * patient is ≥ 18 years and ≤ 75 years of age * eastern cooperative oncology group (ecog) performance status of 0-2 * adequate bone marrow, liver, and renal function: neutrophils\> 1500 /mm3; hemoglobin \> 10 g/dl; platelets \> 100 x109/l; bilirubin \ 1.0 x uln and \ or = 60 ml/min. * written informed consent must be obtained prior to any study related procedures exclusion criteria: * prior radiotherapy to ≥ 40% of bone marrow * previous treatment with cabazitaxel (jevtana®) * prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment * active grade ≥2 peripheral neuropathy * active grade ≥2 stomatitis * active infection requiring systemic antibiotic or anti-fungal medication * active cancer (other than mhrpc) including prior malignancy from which the patient has been disease-free for ≤5 years * known brain or leptomeningeal involvement * history of severe hypersensitivity reaction (≥grade 3) to docetaxel * history of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * history of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone * uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus) * concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome p450 3a4/5 (a 2 weeks wash-out period is necessary for patients who are already on these treatments). participation in any other clinical trial with any investigational drug * patient with reproductive potential not implementing accepted and effective method of contraception the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
soap versus normal salin plus povidone-iodine in ununion wound

Conditions: Wound

Summary: comparison of the effect of water and soap irrigation with povidone-iodine and normal salin treatment of patients with ununion laparatomy or episiotomy wound ( a pilot study)

in comparison of the effect of water and soap irrigation with povidone-iodine and normal salin treatment of patients with ununion laparatomy or episiotomy wound ( a pilot study), we use soap in one group and povidone-iodine and normal salin in other group for irrigation of ununion laparatomy or episiotomy wound.it's require the patients in povidone-iodine and normal salin group be at hospital till wound be able to closed.

Eligibility criteria:
inclusion criteria: * all the women coming to shariati hospital or gynecologist's office with complain of ununion wound of laparatomy or episiotomy enroll to this study exclusion criteria: * patients not satisfacted to participant in the study exclude of it

Keywords: ununion wound soap irrigation povidone-iodine normal salin
temozolomide in treating patients with stage iiib, stage iv, or recurrent non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of temozolomide in treating patients who have stage iiib, stage iv, or recurrent non-small cell lung cancer.

objectives: i. determine the objective response rate to temozolomide in previously treated (closed to accrual 8/01) and chemotherapy-naive patients with advanced non-small cell lung cancer. ii. determine the freedom from progression median, and 1-year and 2-year survival rates in these patients on this regimen. outline: patients are stratified by prior chemotherapy (yes (closed to accrual 8/01) vs no). patients receive oral temozolomide daily for 42 days. treatment repeats every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. patients are followed every 2 months. projected accrual: up to 66 patients (33 per stratum (previously treated stratum closed to accrual 8/01)) will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: stage iiib, iv, or recurrent non-small cell lung cancer for which no curative therapy with surgery, radiation, or combination chemoradiotherapy exists chemotherapy-naive patients: no prior chemotherapy or at least 6 months since prior adjuvant, induction, or radiosensitizing chemotherapy or previously treated patients (closed to accrual 8/01): no more than one prior chemotherapy regimen for relapsed or metastatic disease and/or no more than one prior adjuvant, induction, or radiosensitizing chemotherapy within the past 6 months measurable or evaluable disease cns metastases allowed (previously treated metastases cannot be only site of measurable disease) no brain metastases with prior whole body irradiation patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl renal: creatinine no greater than 2.0 mg/dl other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception during and for 3 months after study no other active invasive malignancies prior concurrent therapy: biologic therapy: prior biologic therapy allowed chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy endocrine therapy: not specified radiotherapy: see disease characteristics recovered from prior radiotherapy surgery: see disease characteristics

Keywords: recurrent non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
extension study: evaluating the safety of oral ziprasidone in the treatment of subjects with schizophrenia

Conditions: Schizophrenia

Summary: to provide treatment to eligible subjects who have successfully completed one of the following phase iii ziprasidone studies, a1281028, a1281044, a1281045 (nct00136994) or a1281088 (nct00143351).


Eligibility criteria:
inclusion criteria: * subjects who have successfully completed a ziprasidone clinical study * patients not hospitalised in an acute psychiatric service * written, informed consent to participation. * female patients of at risk of pregnancy must avoid to remain pregnant; an adequate method of contraception (intrauterine device, implanted contraceptive, oral contraceptive or condom) must be initiated or continued exclusion criteria: psychiatric: * subjects at immediate risk of committing harm to self or others * subjects requiring concurrent treatment with non-study antipsychotic agents * subjects requiring treatment with antidepressants or mood stabilizers * general: * subjects with a history of clinically significant and/or currently relevant hematological, renal (including single kidney), hepatic, gastrointestinal, endocrine (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease), dermatological, oncological, or neurological disease, excluding tardive dyskinesia but including all forms of epilepsy (febrile convulsions in childhood acceptable). the only subjects with known prior malignant disease who are eligible are those with cured prior skin cancer (excluding melanoma). controlled type ii diabetes (glucose \< 180 mg/100 ml at screening and baseline with dietary or oral hypoglycemic treatment) will not be considered a significant medical illness and would not exclude a subject from the study * acute or chronic heart disease * clinically significant ecg abnormalities * subjects with qtc \>= 500 msec (subjects with qtc \>= 450 msec and \< 500 msec should be discussed with the cardiologist who is responsible for all of the centers involved) * concomitant treatment with medications that prolong qtc interval (please review prescribing information of other treatments) * subjects with serum k+ or mg++ outside the normal range * subject with any confirmed laboratory values that deviate from the upper or lower limits of normal prior to study entry, except for clinically insignificant deviations as determined by investigator * known serological evidence of hiv, or acute or chronic hepatitis (with transaminase levels higher than three times upper limit) * pregnant or lactating women * subjects who intend to donate blood or blood products during the 4 weeks prior to the study, during the study or in the 30 days after the study ends * subjects unable or unlikely to follow the study protocol * subjects with a history of neuroleptic malignant syndrome developing from the administration of antipsychotic compounds * known hypersensitivity to ziprasidone or lactose

Keywords: open-label extension ziprasidone study in schizophrenia
mindful self-compassion and perfectionism

Conditions: Perfectionism; Depression; Anxiety; Body Image

Summary: the study is a randomized controlled study. a total of 200 students will be invited to participate in a 5-session mindful self-compassion course aimed at increasing self-compassion and reducing maladaptive perfectionism, anxiety, depression, and unhealthy body image. self-compassion is the ability to show oneself kindness in instances of perceived inadequacy, failure, and suffering by attending to distressing experiences with kindness, mindfulness, and the ability to recognize these as a part of a shared humanity. twelve participants will be randomly selected for pre- and post interviews to qualitatively evaluate outcome. ten participants with high perfectionistic tendencies will be selected to participate in a narrative life story interview.

the investigators will test four hypotheses: 1. at baseline, low levels of maladaptive perfectionism, and lower levels of depression, anxiety and body appreciation - reversed, will be related to greater self-compassion. the investigators expect high level of maladaptive perfectionism to be related to lower baseline self-compassion, higher levels of depression and anxiety and lower levels of body appreciation. 2. the intervention, a five session self-compassion intervention, will be sufficient to induce positive changes in perfectionism and psychological symptoms of anxiety, depression and body-appreciation- reversed. 3. changes in self-compassion will co-vary with changes in maladaptive perfectionism and body appreciation. 4. higher baseline levels of maladaptive perfectionism will predict greater gains from the intervention, because perfectionistic students will have greater need for a self-compassion intervention.

Eligibility criteria:
inclusion criteria: * college/university students exclusion criteria: * n/a